getting to the heart of the matter
Novel therapeutics and diagnostics targeting the multi-factorial root causes of CVD
"Historical development of antibiotics targeting microorganisms led to a cure of infectious disease. An equivalent approach is to target the endothelial glycocalyx to cure CVD by an anti-embolic™ mechanism."
Dr. Joe Tunac
Offerings and IP Summary
Primary Offerings
IP Matter Description
Embotricin™
A rationally synthesized, triple compound, oral therapy with unique mechanisms of action targeting the root causes of CVD proven to prevent and reverse arterial plaques, the hallmark of CVD.
GlycoCardia™
A therapeutic aide and series of diagnostic panels that provide specific information on the associated pathology and risk factors of CVD diseases and stages based on our Glycalyx Detritus Fingerprint™ technology.
Drug Treatment and Biomarker Panel Targeted
to Diseases Due to Multifactorial Ontology of
Glycocalyx Disruption.
Biomarkers of Vascular Disease.
Methods and Compositions for Reversing
Disruption of the Glycocalyx, Inflammation and
Oxidative Damage.
(Draft - to be published Q2, 2021) Natural Animal Model for CVD and Inflammation.
